Research graph
References from Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre <scp>UK</scp> study. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/blood-2011-12-399287
10.1182/blood-2011-12-399287 · External reference
10.1038/leu.2011.351
10.1038/leu.2011.351 · External reference
Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the adult acute lymphoblastic leukemia working Group of the Japanese Society for transplantation and cellular therapy
10.1182/blood-2023-180602 · 2023 · External reference
10.1111/bjh.15973
10.1111/bjh.15973 · External reference
10.1056/nejmoa1609783
10.1056/nejmoa1609783 · External reference
10.1182/bloodadvances.2021005978
10.1182/bloodadvances.2021005978 · External reference
Real‐world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease‐positive B‐cell acute lymphoblastic leukemia: a CIBMTR database analysis
10.1182/blood-2025-6044 · 2025 · External reference
10.1056/nejmoa2406526
10.1056/nejmoa2406526 · External reference
10.1056/nejmoa1709866
10.1056/nejmoa1709866 · External reference
10.1056/nejmoa2406526
10.1056/nejmoa2406526 · External reference
10.1038/s41375-025-02532-7
10.1038/s41375-025-02532-7 · External reference
10.1182/blood.2023022922
10.1182/blood.2023022922 · External reference
10.1182/blood-2009-08-231217
10.1182/blood-2009-08-231217 · External reference
10.1016/j.bbmt.2013.04.014
10.1016/j.bbmt.2013.04.014 · External reference
10.1158/2643-3230.bcd-21-0095
10.1158/2643-3230.bcd-21-0095 · External reference
10.1016/j.bbmt.2013.04.014
10.1016/j.bbmt.2013.04.014 · ExternalCitation · doi-reference
10.1038/leu.2011.351
10.1038/leu.2011.351 · ExternalCitation · doi-reference
10.1038/s41375-025-02532-7
10.1038/s41375-025-02532-7 · ExternalCitation · doi-reference
10.1056/nejmoa1609783
10.1056/nejmoa1609783 · ExternalCitation · doi-reference
10.1056/nejmoa1709866
10.1056/nejmoa1709866 · ExternalCitation · doi-reference
10.1056/nejmoa2406526
10.1056/nejmoa2406526 · ExternalCitation · doi-reference
10.1111/bjh.15973
10.1111/bjh.15973 · ExternalCitation · doi-reference
10.1158/2643-3230.bcd-21-0095
10.1158/2643-3230.bcd-21-0095 · ExternalCitation · doi-reference
10.1182/blood-2009-08-231217
10.1182/blood-2009-08-231217 · ExternalCitation · doi-reference
10.1182/blood-2011-12-399287
10.1182/blood-2011-12-399287 · ExternalCitation · doi-reference
Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the adult acute lymphoblastic leukemia working Group of the Japanese Society for transplantation and cellular therapy
10.1182/blood-2023-180602 · ExternalCitation · doi-reference
Real‐world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease‐positive B‐cell acute lymphoblastic leukemia: a CIBMTR database analysis
10.1182/blood-2025-6044 · ExternalCitation · doi-reference
10.1182/blood.2023022922
10.1182/blood.2023022922 · ExternalCitation · doi-reference
10.1182/bloodadvances.2021005978
10.1182/bloodadvances.2021005978 · ExternalCitation · doi-reference
